Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Hidekazu Hirano"'
Autor:
Tadayoshi Hashimoto, Yoshiaki Nakamura, Yoshito Komatsu, Satoshi Yuki, Naoki Takahashi, Naohiro Okano, Hidekazu Hirano, Koushiro Ohtsubo, Takashi Ohta, Eiji Oki, Tomohiro Nishina, Hisateru Yasui, Hisato Kawakami, Taito Esaki, Nozomu Machida, Ayako Doi, Shogen Boku, Toshihiro Kudo, Yoshiyuki Yamamoto, Akiyoshi Kanazawa, Tadamichi Denda, Masahiro Goto, Naoko Iida, Hiroshi Ozaki, Taro Shibuki, Mitsuho Imai, Takao Fujisawa, Hideaki Bando, Yoichi Naito, Takayuki Yoshino
Publikováno v:
BJC Reports, Vol 2, Iss 1, Pp 1-10 (2024)
Abstract Background While advanced gastrointestinal stromal tumors (GISTs) are primarily treated with tyrosine kinase inhibitors (TKIs), acquired resistance from specific mutations in KIT or PDGFRA frequently occurs. We aimed to assess the utility of
Externí odkaz:
https://doaj.org/article/8d89e02235024fa88d2552871e8438cb
Autor:
Chie Kudo-Saito, Hiroshi Imazeki, Hiroki Ozawa, Hirofumi Kawakubo, Hidekazu Hirano, Narikazu Boku, Ken Kato, Hirokazu Shoji
Publikováno v:
Translational Oncology, Vol 48, Iss , Pp 102075- (2024)
Peritoneal tumor dissemination and subsequent malignant tumor ascites (MTA) occur unexpectedly and repeatedly in patients with gastrointestinal (GI) cancers, and worsen quality of life and prognosis of the patients. Various treatments have been clini
Externí odkaz:
https://doaj.org/article/9a1d813fda324317aa1ac7ae97784b95
Autor:
Toru Kadono, Satoru Iwasa, Toshiharu Hirose, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Atsuo Takashima, Ken Kato
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Background Nivolumab was approved for the treatment of advanced gastric cancer in 2017 in Japan. The aim of this study was to assess the impact of nivolumab in a real‐world clinical setting. Methods This single‐institutional retrospectiv
Externí odkaz:
https://doaj.org/article/fe41231595f14b45a5600e716b2861f8
Autor:
Toru Kadono, Satoru Iwasa, Kengo Nagashima, Kotoe Oshima, Shun Yamamoto, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Yoshitaka Honma, Atsuo Takashima, Ken Kato, Toshikazu Ushijima, Narikazu Boku
Publikováno v:
Cancer Medicine, Vol 12, Iss 8, Pp 9322-9331 (2023)
Abstract Background While the efficacy of immune checkpoint inhibitors (ICIs) reportedly varies among metastatic sites and progression patterns (classified as systemic progression [SP] or mixed progression [MP]), the clinical efficacy of ICIs against
Externí odkaz:
https://doaj.org/article/ede32e6300aa451ea9bc656aaed18946
Autor:
Hiroki Osumi, Atsuo Takashima, Akira Ooki, Yuri Yoshinari, Takeru Wakatsuki, Hidekazu Hirano, Izuma Nakayama, Natsuko Okita, Ryoichi Sawada, Kota Ouchi, Koshiro Fukuda, Shota Fukuoka, Mariko Ogura, Daisuke Takahari, Keisho Chin, Hirokazu Shoji, Ken Kato, Naoki Ishizuka, Narikazu Boku, Kensei Yamaguchi, Eiji Shinozaki
Publikováno v:
Translational Oncology, Vol 35, Iss , Pp 101718- (2023)
Purpose: As circulating tumor DNA (ctDNA) measurement becomes more widespread, the “NeoRAS” phenomenon, where tissue rat sarcoma viral oncogene homolog (RAS) status converts from mutant (MT) to wild-type (WT) after treatment in metastatic colorec
Externí odkaz:
https://doaj.org/article/2dd4356f4b714e61ada692c8cdb096f1
Autor:
Yosui Nojima, Masahiko Aoki, Suyong Re, Hidekazu Hirano, Yuichi Abe, Ryohei Narumi, Satoshi Muraoka, Hirokazu Shoji, Kazufumi Honda, Takeshi Tomonaga, Kenji Mizuguchi, Narikazu Boku, Jun Adachi
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 21, Iss , Pp 2172-2187 (2023)
Apatinib is known to be a highly selective vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with anti-angiogenic and anti-tumor properties. In a phase III study, the objective response rate to apatinib was low. It remains unclear why
Externí odkaz:
https://doaj.org/article/96f2d6f634004bf692af38e6773e75d9
Autor:
Shun Yamamoto, Naoki Sakakibara, Hidekazu Hirano, Chigusa Morizane, Yoshitaka Honma, Susumu Hijioka, Takuji Okusaka, Takahiro Higashi, Akira Kawai
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-8 (2022)
Abstract In November 2013, the first edition of evidence-based guidelines for treatment of gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) was published in Japan. However, whether medical practitioners have adopted the first-line regimens re
Externí odkaz:
https://doaj.org/article/2fbf770325db4322866fff97da0ca57d
Autor:
Hidekazu Hirano, Yuichi Abe, Yosui Nojima, Masahiko Aoki, Hirokazu Shoji, Junko Isoyama, Kazufumi Honda, Narikazu Boku, Kenji Mizuguchi, Takeshi Tomonaga, Jun Adachi
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-13 (2022)
Abstract Phosphoproteomic analysis expands our understanding of cancer biology. However, the feasibility of phosphoproteomic analysis using endoscopically collected tumor samples, especially with regards to dynamic changes upon drug treatment, remain
Externí odkaz:
https://doaj.org/article/23b1b93b6df84053b303f6da1b5e6546
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Despite the clinical outcomes being extremely limited, blocking immune inhibitory checkpoint pathways has been in the spotlight as a promising strategy for treating gastrointestinal cancer. However, a distinct strategy for the successful treatment is
Externí odkaz:
https://doaj.org/article/a023ecd5d8b5432a89b86bae5a4fe430
Autor:
Shigemasa Takamizawa, Hirokazu Shoji, Hidekazu Hirano, Koji Izutsu, Shun Yamamoto, Satoru Iwasa, Yoshitaka Honma, Natsuko Okita, Atsuo Takashima, Ken Kato, Narikazu Boku
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 1, Pp 85-89 (2021)
Severe thrombocytopenia is a rare adverse event of panitumumab. Here, we report the first patient with metastatic colorectal cancer who developed severe thrombocytopenia, diagnosed as panitumumab-associated drug-induced immune thrombocytopenia (DITP)
Externí odkaz:
https://doaj.org/article/f7f9deb3fbdd495a9e8697a053be6d2d